Mette Moustgaard Jeppesen1, Nicole P M Ezendam2,3, Johanna M A Pijnenborg4, M Caroline Vos5, Dorry Boll6, Roy F P M Kruitwagen7, Pernille Tine Jensen8, Lonneke V van de Poll-Franse2,3,9. 1. Department of Gynecology and Obstetrics, Faculty of Health Sciences, Odense University Hospital, Clinical Institute, University of Southern Denmark, Kloevervaenget 10, 10th floor, 5000, Odense C, Denmark. Mette.M.Jeppesen@dadlnet.dk. 2. CoRPS-Center of Research on Psychology in Somatic diseases, Department of Medical and Clinical Psychology, Tilburg University, Tilburg, The Netherlands. 3. Netherlands Comprehensive Cancer Organisation (IKNL), Research Department, Utrecht, the Netherlands. 4. Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, the Netherlands. 5. Department of Obstetrics and Gynecology, Elisabeth-Tweesteden Hospital, Tilburg, the Netherlands. 6. Department of Obstetrics and Gynecology, Catharina Hospital Eindhoven, Eindhoven, The Netherlands. 7. Department of Gynecology and GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands. 8. Department of Gynecology and Obstetrics, Faculty of Health Sciences, Odense University Hospital, Clinical Institute, University of Southern Denmark, Kloevervaenget 10, 10th floor, 5000, Odense C, Denmark. 9. Division of Psychosocial Oncology and Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Abstract
PURPOSE: The purpose of this paper was to assess the impact of survivorship care plan (SCP) provision and moderating factors on health care use following endometrial cancer treatment. METHODS:Women newly diagnosed with endometrial cancer were included in a pragmatic cluster randomized trial at 12 hospitals in the Netherlands and were randomly assigned to SCP or usual care (n = 221; 75% response). The SCP was generated using the web-based Registrationsystem Oncological GYnecology (ROGY) and provided tailored information regarding disease, treatment, and possible late-effects. Cancer-related use of general practitioner, specialist, and additional health care was collected through questionnaires after diagnosis and at 6-, 12-, and 24-month follow-up and compared using linear multilevel regression analyses. RESULTS: Women who received an SCP had more cancer-related primary care visits compared to the usual care arm during the first year after diagnosis (β = 0.7, p < 0.01). At 6-month follow-up, women in the SCP group used more additional health care compared to women receiving usual care (24 vs. 11%, p = 0.04). Women with anxious symptoms (p = 0.03) and women who received radiotherapy (p = 0.01) had a higher primary care use within the first year after treatment, when receiving an SCP. CONCLUSIONS: The SCP increases primary health care consumption the first year after treatment, particularly in women treated with radiotherapy and women with anxious symptoms. IMPLICATIONS FOR CANCER SURVIVORS: These findings imply that the SCP enables women in need of supportive care to seek relevant care at an early stage after treatment. Whether this results in improved patient-reported outcomes in the long-term needs to be further studied.
RCT Entities:
PURPOSE: The purpose of this paper was to assess the impact of survivorship care plan (SCP) provision and moderating factors on health care use following endometrial cancer treatment. METHODS:Women newly diagnosed with endometrial cancer were included in a pragmatic cluster randomized trial at 12 hospitals in the Netherlands and were randomly assigned to SCP or usual care (n = 221; 75% response). The SCP was generated using the web-based Registrationsystem Oncological GYnecology (ROGY) and provided tailored information regarding disease, treatment, and possible late-effects. Cancer-related use of general practitioner, specialist, and additional health care was collected through questionnaires after diagnosis and at 6-, 12-, and 24-month follow-up and compared using linear multilevel regression analyses. RESULTS:Women who received an SCP had more cancer-related primary care visits compared to the usual care arm during the first year after diagnosis (β = 0.7, p < 0.01). At 6-month follow-up, women in the SCP group used more additional health care compared to women receiving usual care (24 vs. 11%, p = 0.04). Women with anxious symptoms (p = 0.03) and women who received radiotherapy (p = 0.01) had a higher primary care use within the first year after treatment, when receiving an SCP. CONCLUSIONS: The SCP increases primary health care consumption the first year after treatment, particularly in women treated with radiotherapy and women with anxious symptoms. IMPLICATIONS FOR CANCER SURVIVORS: These findings imply that the SCP enables women in need of supportive care to seek relevant care at an early stage after treatment. Whether this results in improved patient-reported outcomes in the long-term needs to be further studied.
Entities:
Keywords:
Cancer survivorship; Endometrial carcinoma; Gynecologic oncology; SCP
Authors: Michael Jefford; Karla Gough; Allison Drosdowsky; Lahiru Russell; Sanchia Aranda; Phyllis Butow; Jo Phipps-Nelson; Jane Young; Mei Krishnasamy; Anna Ugalde; Dorothy King; Andrew Strickland; Michael Franco; Robert Blum; Catherine Johnson; Vinod Ganju; Jeremy Shapiro; Geoffrey Chong; Julie Charlton; Andrew Haydon; Penelope Schofield Journal: Oncologist Date: 2016-06-15
Authors: N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes Journal: J Natl Cancer Inst Date: 1993-03-03 Impact factor: 13.506
Authors: Christine E Hill-Kayser; Carolyn C Vachani; Margaret K Hampshire; Gloria Di Lullo; Linda A Jacobs; James M Metz Journal: Cancer Date: 2013-08-06 Impact factor: 6.860
Authors: Katherine S Virgo; Catherine C Lerro; Carrie N Klabunde; Craig Earle; Patricia A Ganz Journal: J Clin Oncol Date: 2013-05-20 Impact factor: 44.544
Authors: Rebecca E Hill; Claire E Wakefield; Richard J Cohn; Joanna E Fardell; Mary-Ellen E Brierley; Emily Kothe; Paul B Jacobsen; Kate Hetherington; Rebecca Mercieca-Bebber Journal: Oncologist Date: 2019-10-25
Authors: Rebecca E Hill; Claire E Wakefield; Richard J Cohn; Joanna E Fardell; Mary-Ellen E Brierley; Emily Kothe; Paul B Jacobsen; Kate Hetherington; Rebecca Mercieca-Bebber Journal: Oncologist Date: 2019-10-25
Authors: Leah L Zullig; Katherine Ramos; Callie Berkowitz; Julie J Miller; Rowena J Dolor; Bridget F Koontz; S Yousuf Zafar; D Hutch Allen; Jennifer A Tenhover; Hayden B Bosworth Journal: J Cancer Educ Date: 2019-06 Impact factor: 2.037
Authors: Belle H de Rooij; Nicole P M Ezendam; M Caroline Vos; Johanna M A Pijnenborg; Dorry Boll; Roy F P M Kruitwagen; Lonneke V van de Poll-Franse Journal: Cancer Date: 2018-11-30 Impact factor: 6.860
Authors: Beverley L Høeg; Pernille E Bidstrup; Randi V Karlsen; Anne Sofie Friberg; Vanna Albieri; Susanne O Dalton; Lena Saltbæk; Klaus Kaae Andersen; Trine Allerslev Horsboel; Christoffer Johansen Journal: Cochrane Database Syst Rev Date: 2019-11-21
Authors: Erin L O'Hea; Samantha Creamer; Julie M Flahive; Beth A Keating; Candace R Crocker; Shannon R Williamson; Kathryn L Edmiston; Tina Harralson; Edwin D Boudreaux Journal: J Psychosoc Oncol Date: 2021-06-20
Authors: Claire Snyder; Youngjee Choi; Amanda L Blackford; Jennifer DeSanto; Nancy Mayonado; Susan Rall; Sharon White; Janice Bowie; David E Cowall; Fabian Johnston; Robert L Joyner; Joan Mischtschuk; Kimberly S Peairs; Elissa Thorner; Phuoc T Tran; Antonio C Wolff; Katherine C Smith Journal: J Natl Cancer Inst Date: 2022-01-11 Impact factor: 11.816